Mortality Reduction After Oral Azithromycin: Mortality Study

Completed · Phase 4 · Has a placebo group

Conditions studied: Childhood Mortality

In brief

Our long-term goal is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood mortality. We propose a single multi-site (multi-country), cluster-randomized trial comparing communities randomized to oral azithromycin with those randomized to placebo. We hypothesize that mass azithromycin treatments will reduce childhood mortality.

Key facts

Study ID

NCT02047981

Run by

University of California, San Francisco

People needed

190238

Starts

2014-12-01

Expected to finish

2018-09-01

Last updated by the study team

2022-11-08

Who can join

Age: 0 and older, up to 5. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Communities
• The community location in target district.
• The community leader consents to participation in the trial
• The community's estimated population is between 200-2,000 people.
• The community is not in an urban area.
• Individuals - All children aged 1-60 months (up to but not including the 5th birthday), as assessed via biannual census.

You may not qualify if…

• Individuals
• Refusal of village chief (for village inclusion), or refusal of parent or guardian (for individual inclusion)

Where it is running

• UCSF Proctor Foundation — San Francisco, California, United States
• Johns Hopkins University — Baltimore, Maryland, United States
• College of Medicine at the University of Malawi, Blantyre — Blantyre, Malawi
• The Carter Center, Niger — Niamey, Niger
• Kongwa Trachoma Project — Kongwa, Tanzania
• London School of Hygiene & Tropical Medicine — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.